The main focus of this comprehensive policy guide—the first of its kind solely dedicated to the region—is to analyze the effect of bilateral trade agreements on public health regimes and access to medicines in the countries of the Eastern Mediterranean Region.
Drug patent restrictions by the United States and the European Union in trade negotiations with emerging countries will harm the Thai pharmaceutical industry and affect local patients, say researchers.
Marking strong protest against the proposed signing of the European Union-India Free Trade Agreement on IP Provision, a mass protest rally was taken out today jointly by the Centre for Social Development in collaboration with organisation working on drugs and HIV/AIDS, North East Diaglogue Forum, Women Action for Development and Bosco Mangal, Chingmeirong Don Bosco Society, Imphal.
A confidential Trans-Pacific Partnership Agreement negotiating paper authored by New Zealand suggests that the trade pact’s patent and copyright provisions be no more stringent than existing global standards
Fears have been raised that cheap life-saving anti-retroviral drugs may no longer be available in Kenya if a trade agreement between the EU and India is concluded.
The government is coming under increasing attack from activists for pushing ahead with EU-Thailand free trade agreement talks which include alcohol, tobacco and medicines.
The EU claims data exclusivity is required under international law. It is not. It also claims that there will be no harm to access to medicines. But other countries have learned the hard way how harmful it can be.
Alors que des responsables indiens et européens se rencontrent à Bruxelles pour mettre au point les détails d’un accord de libre-échange, des activistes de la société civile s’inquiètent que l’accord puisse déboucher sur une protection renforcée de la propriété intellectuelle qui pourrait réduire l’accès aux médicaments génériques indiens bon marché.
MSF staff and supporters rally outside the offices of the European Commission to deliver an open letter of protest against ongoing trade talks between the European Union and India that could damage access to affordable medicines.
How a trade deal being brokered between Europe and India could cut off the developing world’s supply of cheap medicines. Al Jazeera reports.
Canada’s pharmaceutical industry and the European Union have been quietly lobbying for changes that could give brand-name drugs several years more patent protection here — and potentially add hundreds of millions of dollars to Canadian medication costs annually.
Hundreds of public interest groups across the world have jointly urged prime minister Manmohan Singh not to sign the proposed free trade agreement (FTA) with European Union as the Centre’s role in medicines supply is under threat due to the intellectual property provisions included in the pact.
The EC is seeking a trade agreement with India which will restrict its generic companies from making cheap copycat drugs for poor countries, says MSF, which launches a campaign to oppose this and other allegedly restrictive EC practices today
We are calling for an international week of joint action from 4 October 2010 to 9 October 2010 to call upon the Government of India to reject
the EU-India FTA, especially the provisions relating to intellectual
property rights and investment.
In some countries, up to 90% of children with AIDS are dependent on India’s cheap, generic drugs.
We request organizations and individuals across the world to join Delhi Network of Positive People in a sign on letter to issue a appeal to the Indian government to ’not sign on’ to any IP provisions in the FTA negotiations.
A new study from UNITAID warns that free trade agreements India is currently negotiating may close the tap on affordable medicines for AIDS patients.
If commerce ministry officials have their way in negotiations, all future free trade agreements (FTA) will include a clause protecting India’s interests against third-party agreements, which include FTA partner nations.
The Indian government’s doublespeak on generic medicines has the stakeholders in a tizzy.